ASCO GU 2018 Prostate Cancer - Results from #40

Viewing 41-60 of 88 articles

ASCO GU 2018: Outcomes in Patients with Advanced Prostate Cancer And Inactivating Germline Mutations in BRCA2 or ATM

ASCO GU 2018: Incorporating Genomics Into the Management of Systemic Therapy: Advances and Practicality

ASCO GU 2018: Impact of Sexual Orientation on Contemporary Rates of Prostate Cancer Screening

ASCO GU 2018: Why are Low-risk Prostate Cancers (Pca) Treated Aggressively? A Population-based Cohort Analysis

ASCO GU 2018: Statin use and Outcomes of Patients with mCRPC Being Treated with Abiraterone

ASCO GU 2018: A National Survey of Radiation Oncologists and Urologists on Active Surveillance for Low-risk Prostate Cancer

ASCO GU 2018: When Can Active Surveillance Be Less Active? Prediction of Long-term Non-reclassification for Men with Low-risk Prostate Cancer

ASCO GU 2018: TPS 159 -What Fixes PSA Screening Guidelines Gone Wrong?

ASCO GU 2018: Can free PSA be used as a biomarker in biochemical recurrence after surgery to predict CRPC?

ASCO GU 2018: Radium-223 Retreatment in an International, Open-label, Phase I/II Study in Patients with CRPC and Bone Metastases: 2-year Follow-up

ASCO GU 2018: Abiraterone acetate plus prednisone 5 mg daily in metastatic castration-naïve prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase III trial

ASCO GU 2018: Enzalutamide vs Bicalutamide in Combination with Androgen Deprivation in mHSPC

ASCO GU 2018: Indirect Treatment Comparison of Abiraterone Acetate Plus Prednisone and Docetaxel on Patient-reported Outcomes in Metastatic Castration-naïve Prostate Cancer (mCNPC)

ASCO GU 2018: Overall Survival of Patients with Metastatic Prostate Cancer Starting ADT with Degarelix, A Gonadotropin-releasing Hormone Antagonist

ASCO GU 2018: The Clinical Role of Germline and Somatic Genomics and the Risk-Stratification of Localized Prostate Cancer

ASCO GU 2018: DNA Repair Gene Panel Mutations in Young Onset Prostate Cancer Cases in The United Kingdom

ASCO GU 2018: Visceral Metastases on Abiraterone vs. Placebo: A Post-hoc Analysis of Mode of Radiographic Progression In COU-AA-302

ASCO GU 2018: Occurrence of pathologic stage T3 disease at radical prostatectomy with ISUP grade group 1 (Gleason 3+3=6) prostate cancer

ASCO GU 2018: Optimal Timing of Post-prostatectomy Radiotherapy For Prostate Cancer With High-risk Pathologic Features: A Multi-institutional Analysis

ASCO GU 2018: Evaluation of a Predefined as Threshold in a Large Cohort of Men with Localized Prostate Cancer

1
2
3
4
5